Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management
Количественная оценка задержки опорожнения желудка при применении агонистов рецепторов глюкагоноподобного пептида-1: систематический обзор и метаанализ с выводами для ведения пациентов в периоперационном периоде
2024-04-18
SCID: 54.1/wzzujzsx
Discuss with AI
GLP-1 receptor agonistsacetaminophen absorption testgastric emptyinggastric emptying scintigraphyperiprocedural management
Figures from the paper
Abstract (AI)
INTRODUCTION: Divergent recommendations for periprocedural management of glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA) medications rely on limited evidence. We performed a systematic review and meta-analysis to provide quantitative measures of gastric emptying relevant to mechanisms of weight loss and to periprocedural management of GLP-1 RA. We hypothesized that the magnitude of gastric emptying delay would be low and of limited clinical significance to procedural sedation risks. METHODS: A protocolized search identified studies on GLP-1 RA that quantified gastric emptying measures. Pooled estimates using random effects were presented as a weighted mean difference with 95% confidence intervals (CIs). Univariate meta-regression was performed to assess the influence of GLP-1 RA type, short-acting vs long-acting mechanism of action, and duration of treatment on gastric emptying. RESULTS: Fifteen studies met the inclusion criteria. Five studies (n = 247) utilized gastric emptying scintigraphy. Mean T 1/2 was 138.4 minutes (95% CI 74.5-202.3) for GLP-1 RA vs 95.0 minutes (95% CI 54.9-135.0) for placebo, with a pooled mean difference of 36.0 minutes (95% CI 17.0-55.0, P < 0.01, I2 = 79.4%). Ten studies (n = 411) utilized the acetaminophen absorption test, with no significant delay in gastric emptying measured by T max , area under the curve (AUC) 4hr , and AUC 5hr with GLP-1 RA ( P > 0.05). On meta-regression, the type of GLP-1 RA, mechanism of action, and treatment duration did not impact gastric emptying ( P > 0.05). DISCUSSION: While a gastric emptying delay of ∼36 minutes is quantifiable on GLP-1 RA medications, it is of limited magnitude relative to standard periprocedural fasting periods. There were no substantial differences in gastric emptying on modalities reflective of liquid emptying (acetaminophen absorption test), particularly at time points relevant to periprocedural care.
Key Findings
1
A systematic review and meta-analysis included 15 studies quantifying gastric emptying in patients receiving GLP-1 receptor agonists.
2
Acetaminophen absorption tests found no significant GLP-1 RA-related delay in liquid gastric emptying across T max, 4-hour AUC, or 5-hour AUC measures.
3
GLP-1 receptor agonist type, short- versus long-acting mechanism, and treatment duration did not significantly influence gastric emptying outcomes.
4
Gastric emptying scintigraphy showed a pooled GLP-1 RA-associated delay of 36.0 minutes versus placebo (95% CI, 17.0–55.0; P < 0.01).
5
The approximately 36-minute delay was considered limited relative to standard periprocedural fasting periods, suggesting modest implications for procedural sedation risk.
Research Object
Gastric emptying in patients receiving glucagon-like peptide-1 receptor agonists
Research Subject
The magnitude and clinical relevance of GLP-1 receptor agonist–associated gastric emptying delay, including its dependence on drug type, mechanism, and treatment duration
Publication Details
Publication Date
2024-04-18
Journal
Publisher
ISSN
Cited by
88
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
Obesity Management in Adults2023
Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control2022
Postprandial symptoms in patients with symptoms of gastroparesis: roles of gastric emptying and accommodation2022
Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double‐blind, placebo‐controlled trial2020
RoB 2: a revised tool for assessing risk of bias in randomised trials2019
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions2016